Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Laura M. de Jong"'
Autor:
Menno Hoekstra, Laura M. de Jong, Rick van der Geest, Lidewij R. de Leeuw, Rani Krisnamurthi, Janine J. Geerling, Miranda Van Eck
Publikováno v:
Biomolecules, Vol 14, Iss 4, p 429 (2024)
Preclinical studies regarding the potential of liver X receptor (LXR) agonists to inhibit macrophage foam cell formation and the development of atherosclerotic lesions are generally executed in mice fed with Western-type diets enriched in cholesterol
Externí odkaz:
https://doaj.org/article/81278c42970048989268f38ff1cfb5fb
Autor:
Laura M. de Jong, Soukayna Boussallami, Elena Sánchez-López, Martin Giera, Maarten E. Tushuizen, Menno Hoekstra, Lukas J. A. C. Hawinkels, Robert Rissmann, Jesse J. Swen, Martijn L. Manson
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Introduction: Pharmacogenetics-informed drug prescribing is increasingly applied in clinical practice. Typically, drug metabolizing phenotypes are determined based on genetic test results, whereupon dosage or drugs are adjusted. Drug-drug-interaction
Externí odkaz:
https://doaj.org/article/dfd4b7aa0cba4a3db6f51c0bbc61c879
Autor:
Laura M. de Jong, Zhengzheng Zhang, Yvette den Hartog, Timothy J. P. Sijsenaar, Renata Martins Cardoso, Martijn L. Manson, Thomas Hankemeier, Peter W. Lindenburg, Daniela C. F. Salvatori, Miranda Van Eck, Menno Hoekstra
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-12 (2022)
Abstract Protein arginine methyltransferase 3 (PRMT3) is a co-activator of liver X receptor capable of selectively modulating hepatic triglyceride synthesis. Here we investigated whether pharmacological PRMT3 inhibition can diminish the hepatic steat
Externí odkaz:
https://doaj.org/article/2acc68e974784fab8a54729f6409f243
Autor:
Laura M. de Jong, Sylvia D. Klomp, Nicoline Treijtel, Robert Rissmann, Jesse J. Swen, Martijn L. Manson
Publikováno v:
British Journal of Clinical Pharmacology, 88(10), 4387-4402
British Journal of Clinical Pharmacology, 88(10), 4387-4402. WILEY
British Journal of Clinical Pharmacology, 88(10), 4387-4402. WILEY
Aim: Use of immunomodulating therapeutics for immune-mediated inflammatory diseases may cause disease-drug-drug interactions (DDDIs) by reversing inflammation-driven alterations in the metabolic capacity of cytochrome P450 enzymes. European Medicine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93343a4a2817e269defa8b78634b35e9
https://hdl.handle.net/1887/3483880
https://hdl.handle.net/1887/3483880
Autor:
Laura M. de Jong, Lidewij R. de Leeuw, Mara J. Kröner, Joya E. Nahon, Menno Hoekstra, Miranda Van Eck
Publikováno v:
Biochimica et Biophysica Acta: Molecular Basis of Disease, 1865(6), 1402-1409
The nuclear receptor liver X receptor (LXR) impacts on cholesterol metabolism as well as hepatic lipogenesis via transcriptional regulation. It is proposed that inhibition of the protein arginine methyltransferase 3 (PRMT3) uncouples these two transc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fe7c2c65e52698e12e2b6eb36f8cb97
https://hdl.handle.net/1887/85615
https://hdl.handle.net/1887/85615
Publikováno v:
Genes
Genes, 11(12). MDPI
Genes, Vol 11, Iss 1509, p 1509 (2020)
Genes, 11(12). MDPI
Genes, Vol 11, Iss 1509, p 1509 (2020)
Personalized medicine strives to optimize drug treatment for the individual patient by taking into account both genetic and non-genetic factors for drug response. Inflammation is one of the non-genetic factors that has been shown to greatly affect th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ee9da2bb641ca8d39f6c264544c5625
https://doi.org/10.3390/genes11121509
https://doi.org/10.3390/genes11121509